The impact of timing and modalities of dental prophylaxis on the risk of 5-fluorouracil-related oral mucositis in patients with head and neck cancer: a nationwide population-based cohort study.
5-Fluorouracil–related oral mucositis
Chlorohexidine
Dental prophylaxis
Fluoride gel application
Head and neck cancer
Scaling
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
13
02
2020
accepted:
13
10
2020
pubmed:
20
10
2020
medline:
18
5
2021
entrez:
19
10
2020
Statut:
ppublish
Résumé
This study investigated the impact of dental prophylaxis on 5-fluorouracil (5-FU)-related oral mucositis (OM) according to the head and neck cancer (HNC) locations and treatment times. A total of 13,969 HNC participants, including 482 5-FU-related OM subjects and 13,487 comparisons were enrolled from the Longitudinal Health Insurance Database for Catastrophic Illness Patients of Taiwan between 2000 and 2008. All subjects were stratified into subgroups based on the times to perform chlorhexidine use, scaling, and fluoride application before 5-FU administration. The dental prophylaxis related to 5-FU-related OM was estimated by multiple logistic regression and represented with odds ratio (OR) and 95% confidence interval (CI). Fluoride gel application and scaling significantly impacted on OM development (p < 0.001), and the joint effect of fluoride gel and scaling induced 5-FU-related OM (OR = 3.46, 95% CI = 2.39-5.01). The risk of OM was raised 2.25-fold as scaling within 3 weeks before 5-FU-related chemotherapy (95% CI = 1.81-2.81), and a 3.22-fold increased risk of OM while fluoride gel was applied during 5-FU-related treatment (95% CI = 1.46-7.13). Dental prophylaxis significantly affected 5-FU-related OM in the HNC population. A short interval between dental scaling or fluoride application and 5-FU administration may be associated with higher prevalence of OM. Scaling simultaneously combined with chlorohexidine promoted 5-FU-related OM in specific HNC patients excluding the oral cancer and nasopharyngeal cancer population. Proper timing of the prophylactic dental treatments prior to 5-FU therapy could reduce the risk to develop 5-FU-related OM.
Identifiants
pubmed: 33074358
doi: 10.1007/s00520-020-05825-y
pii: 10.1007/s00520-020-05825-y
doi:
Substances chimiques
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3163-3171Subventions
Organisme : Chang Gung Memorial Hospital, Linkou
ID : CMRPG3I0151
Organisme : Chang Gung Memorial Hospital, Linkou
ID : CMRPG3E1341
Organisme : Chang Gung Memorial Hospital, Linkou
ID : CMRPG3H1671
Organisme : Chang Gung Memorial Hospital, Linkou
ID : CMRPG3G0301
Organisme : Far Eastern Memorial Hospital
ID : FEMH-2019-C-039
Organisme : Far Eastern Memorial Hospital
ID : FEMH-2020-C-030
Organisme : Ministry of Health and Welfare
ID : MOHW109-TDU-B-212-114004
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 108-2321-B-039-003
Organisme : China Medical University Hospital
ID : DMR-108-103
Références
Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3(5):330–338
doi: 10.1038/nrc1074
Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, Bennett CL (2008) Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 113(6):1446–1452
doi: 10.1002/cncr.23714
Joshi VK (2010) Dental treatment planning and management for the mouth cancer patient. Oral Oncol 46(6):475–479
doi: 10.1016/j.oraloncology.2010.03.010
Mariotti AJ, Rumpf DA (1999) Chlorhexidine-induced changes to human gingival fibroblast collagen and non-collagen protein production. J Periodontol 70(12):1443–1448
doi: 10.1902/jop.1999.70.12.1443
Wurtz T, Houari S, Mauro N, MacDougall M, Peters H, Berdal A (2008) Fluoride at non-toxic dose affects odontoblast gene expression in vitro. Toxicology 249(1):26–34
doi: 10.1016/j.tox.2008.04.013
Chang CT, Liu SP, Muo CH, Tsai CH, Huang YF (2017) Dental prophylaxis and osteoradionecrosis: a population-based study. J Dent Res 96(5):531–538
doi: 10.1177/0022034516687282
Huang YF, Liu SP, Muo CH, Tsai CH, Chang CT (2020) The association between dental therapy timelines and osteoradionecrosis: a nationwide population-based cohort study. Clin Oral Investig 24(1):455–463
doi: 10.1007/s00784-019-02866-4
Qutob AF, Allen G, Gue S, Revesz T, Logan RM, Keefe D (2013) Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment : a retrospective and a prospective study. Support Care Cancer 21(4):1113–1120
doi: 10.1007/s00520-012-1633-2
Epstein JB, Güneri P, Barasch A (2014) Appropriate and necessary oral care for people with cancer: guidance to obtain the right oral and dental care at the right time. Support Care Cancer 22(7):1981–1988
doi: 10.1007/s00520-014-2228-x
Morais MO, Martins AFL, de Jesus APG, de Sousa Neto SS, da Costa AWF, Pereira CH, Oton-Leite AF, de Freitas NMA, Leles CR, Mendonça EF (2020) A prospective study on oral adverse effects in head and neck cancer patients submitted to a preventive oral care protocol. Support Care Cancer 28(9):4263–4273
doi: 10.1007/s00520-019-05283-1
Sroussi HY, Epstein JB, Bensadoun RJ, Saunders DP, Lalla RV, Migliorati CA, Heaivilin N, Zumsteg ZS (2017) Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer medicine 6(12):2918–2931
doi: 10.1002/cam4.1221
Khaw A, Logan R, Keefe D, Bartold M (2014) Radiation-induced oral mucositis and periodontitis - proposal for an inter-relationship. Oral Dis 20(3):e7–e18
doi: 10.1111/odi.12199
Saito H, Watanabe Y, Sato K, Ikawa H, Yoshida Y, Katakura A, Takayama S, Sato M (2014) Effects of professional oral health care on reducing the risk of chemotherapy-induced oral mucositis. Support Care Cancer 22(11):2935–2940
doi: 10.1007/s00520-014-2282-4
Epstein JB, Wong FL, Stevenson-Moore P (1987) Osteoradionecrosis: clinical experience and a proposal for classification. J Oral Maxillofac Surg 45(2):104–110
doi: 10.1016/0278-2391(87)90399-5
Marx RE, Johnson RP (1987) Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral surgery, oral medicine, and oral pathology 64(4):379–390
doi: 10.1016/0030-4220(87)90136-8
Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M (1994) Prevention of Oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 30b(2):93–97
doi: 10.1016/0964-1955(94)90059-0
Deng J, Jackson L, Epstein JB, Migliorati CA, Murphy BA (2015) Dental demineralization and caries in patients with head and neck cancer. Oral Oncol 51(9):824–831
doi: 10.1016/j.oraloncology.2015.06.009
Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mookanamparambil L, Ramoni M (2007) Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 43(3):289–300
doi: 10.1016/j.oraloncology.2006.03.014
De Jong HP, Schakenraad JM, Busscher HJ (1988) Spreading of human fibroblasts on pretreated human root dentine. Journal de biologie buccale 16(1):31–34
pubmed: 3165091
Russi EG, Raber-Durlacher JE, Sonis ST (2014) Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. Mediat Inflamm 2014:518261
doi: 10.1155/2014/518261
Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(15):3562–3567
doi: 10.1200/JCO.2005.01.057
Kua VF, Ismail F, Chee Ee Phua V, Aslan NM (2013) Carboplatin/5-fluorouracil as an alternative to cisplatin/5-fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Asian Pacific Journal of Cancer Prevention: APJCP 14(2):1121–1126
doi: 10.7314/APJCP.2013.14.2.1121
Sonis ST (2004) Pathobiology of mucositis. Semin Oncol Nurs 20(1):11–15
doi: 10.1053/j.soncn.2003.10.003
McGaw WT, Belch A (1985) Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen. Oral Surgery, Oral Medicine, and Oral Pathology 60(3):275–280
doi: 10.1016/0030-4220(85)90311-1
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P (2020) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126(19):4423–4431
doi: 10.1002/cncr.33100
Cardona A, Balouch A, Abdul MM, Sedghizadeh PP, Enciso R (2017) Efficacy of chlorhexidine for the prevention and treatment of oral mucositis in cancer patients: a systematic review with meta-analyses. Journal of Oral Pathology & Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 46(9):680–688
doi: 10.1111/jop.12549
Raber-Durlacher JE, Elad S, Barasch A (2010) Oral mucositis. Oral Oncol 46(6):452–456
doi: 10.1016/j.oraloncology.2010.03.012
Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, Quinn B, Epstein JB, Blijlevens NM, Waltimo T, Passweg JR, Correa ME, Dahllof G, Garming-Legert KU, Logan RM, Potting CM, Shapira MY, Soga Y, Stringer J, Stokman MA, Vokurka S, Wallhult E, Yarom N, Jensen SB (2015) Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer 23(1):223–236
doi: 10.1007/s00520-014-2378-x
Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, Fall-Dickson JM, Johansen J, Ameringer S, Kataoka T, Weikel D, Eilers J, Ranna V, Vaddi A, Lalla RV, Bossi P, Elad S (2019) Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27(10):3949–3967
doi: 10.1007/s00520-019-04848-4